The present application relates to compounds of formula (I) wherein the definitions are as described in claim 1. It has been found that the present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).
本申请涉及式(I)的化合物,其中定义如权利要求1所述。已发现这些化合物是治疗抑郁症、疼痛、精神病、帕
金森病、精神分裂症、焦虑和注意力缺陷多动障碍(ADHD)的高潜力NK-3受体拮抗剂。